CAR T-Cell Response Rate Tops 80% in NHL Trial – OncLive
OncLive |
CAR T-Cell Response Rate Tops 80% in NHL Trial
OncLive More than 80% of patients with refractory non-Hodgkin lymphoma (NHL) achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (KTE-C19), results of a pivotal phase II trial showed.1 |
